Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Circulation ; 103(17): 2138-43, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11331253

ABSTRACT

BACKGROUND: Catheter-based myocardial gene transfer (GTx) has not been previously tested in human subjects. Accordingly, we performed a pilot study to investigate the feasibility and safety of catheter-based myocardial GTx of naked plasmid DNA encoding vascular endothelial growth factor-2 (phVEGF-2) in patients with chronic myocardial ischemia. METHODS AND RESULTS: A steerable, deflectable 8F catheter incorporating a 27-guage needle was advanced percutaneously to the left ventricular myocardium of 6 patients with chronic myocardial ischemia. Patients were randomized (1:1) to receive phVEGF-2 (total dose, 200 microgram), which was administered as 6 injections into ischemic myocardium (total, 6.0 mL), or placebo (mock procedure). Injections were guided by NOGA left ventricular electromechanical mapping. Patients initially randomized to placebo became eligible for phVEGF-2 GTx if they had no clinical improvement 90 days after their initial procedure. Catheter injections (n=36) caused no changes in heart rate or blood pressure. No sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforations were observed. phVEGF-2-transfected patients experienced reduced angina (before versus after GTx, 36.2+/-2.3 versus 3.5+/-1.2 episodes/week) and reduced nitroglycerin consumption (33.8+/-2.3 versus 4.1+/-1.5 tablets/week) for up to 360 days after GTx; reduced ischemia by electromechanical mapping (mean area of ischemia, 10.2+/-3.5 versus 2.8+/-1.6 cm(2), P=0.04); and improved myocardial perfusion by SPECT-sestamibi scanning for up to 90 days after GTx when compared with images obtained after control procedure. Conclusions-This randomized trial of catheter-based phVEGF-2 myocardial GTx provides preliminary indications regarding the feasibility, safety, and potential efficacy of percutaneous myocardial GTx to human left ventricular myocardium.


Subject(s)
Cardiac Catheterization , DNA, Recombinant/administration & dosage , Myocardial Ischemia/therapy , Neovascularization, Physiologic/genetics , Transfection , Vascular Endothelial Growth Factors/therapeutic use , Ventricular Function, Left , Aged , DNA, Recombinant/genetics , DNA, Recombinant/therapeutic use , Feasibility Studies , Female , Heart Ventricles/physiopathology , Humans , Male , Myocardial Ischemia/diagnostic imaging , Myocardial Ischemia/physiopathology , Pilot Projects , Safety , Tomography, Emission-Computed, Single-Photon , Treatment Outcome , Vascular Endothelial Growth Factors/genetics
2.
Anesth Analg ; 92(1): 19-25, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11133594

ABSTRACT

UNLABELLED: Gene transfer for therapeutic angiogenesis represents a novel treatment for medically intractable angina in patients judged not amenable to further conventional revascularization. We describe the anesthetic management of 30 patients with class 3 or 4 angina, enrolled in a Phase 1 clinical trial to assess the safety and bioactivity of direct myocardial gene transfer of naked DNA-encoding vascular endothelial growth factor (phVEGF(165)), as sole therapy for refractory angina. The phVEGF(165) was injected directly into the myocardium through a mini-thoracotomy. All patients had major clinical predictors for adverse perioperative cardiac complications. Fast-track anesthetic management with remifentanil and desflurane, multimodal analgesia, and aggressive hemodynamic control with nitroglycerin and esmolol were used. All patients tolerated anesthesia and surgery without problems. No perioperative myocardial infarction, hemodynamic instability, or ventricular failure occurred. VEGF injections caused no clinically significant changes in cardiovascular function. Mean hospital stay was 3.8 days. There was one late death (5 months postoperative). Twenty-nine of 30 patients experienced reduced angina (56.2 +/- 4.1 episodes/week preoperatively versus 3.8 +/- 1.6 postoperatively, P < 0.0001) and reduced sublingual nitroglycerin consumption (60.1 +/- 4.4 tablets/week preoperatively versus 2.9 +/- 1.1 postoperatively, P < 0.0001). IMPLICATIONS: Previously revascularized patients now judged "inoperable," continue to present with chronic, recurrent angina. Our study describes the anesthetic considerations and management of such patients treated with a novel approach by using gene therapy to stimulate angiogenesis and improve perfusion to ischemic myocardium.


Subject(s)
Anesthesia, General/methods , Angina Pectoris/therapy , DNA/administration & dosage , Endothelial Growth Factors/genetics , Genetic Therapy/methods , Lymphokines/genetics , Myocardial Revascularization/methods , DNA/genetics , Drug Administration Routes , Female , Hemodynamics , Humans , Male , Middle Aged , Myocardium , Neovascularization, Physiologic/genetics , Nitroglycerin/administration & dosage , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Vasodilator Agents/administration & dosage
3.
Circulation ; 102(9): 965-74, 2000 Aug 29.
Article in English | MEDLINE | ID: mdl-10961959

ABSTRACT

BACKGROUND: NOGA left ventricular (LV) electromechanical mapping (EMM) can be used to distinguish among infarcted, ischemic, and normal myocardium. We investigated the use of percutaneous LV EMM to assess the efficacy of myocardial gene transfer (GTx) of naked plasmid DNA encoding for vascular endothelial growth factor (phVEGF(165)), administered during surgery by direct myocardial injection in patients with chronic myocardial ischemia. METHODS AND RESULTS: A total of 13 consecutive patients (8 men, mean age 60.1+/-2. 3 years) with chronic stable angina due to angiographically documented coronary artery disease, all of whom had failed conventional therapy (drugs, PTCA, and/or CABG), were treated with direct myocardial injection of phVEGF(165) via a minithoracotomy. Foci of ischemic myocardium were identified on LV EMM by preserved viability associated with an impairment in linear local shortening. Myocardial viability, defined by mean unipolar and bipolar voltage recordings >/=5 and >/=2 mV, respectively, did not change significantly after GTx. Analysis of linear local shortening in areas of myocardial ischemia, however, disclosed significant improvement after (15.26+/-0.98%) versus before (9.94+/-1.53%, P:=0. 004) phVEGF(165) GTx. The area of ischemic myocardium was consequently reduced from 6.45+/-1.37 cm(2) before GTx to 0.95+/-0. 41 cm(2) after GTx (P:=0.001). These findings corresponded to improved perfusion scores calculated from single-photon emission CT-sestamibi myocardial perfusion scans recorded at rest (7.4+/-2.1 before GTx versus 4.5+/-1.4 after GTx, P:=0.009) and after pharmacological stress (12.8+/-2.7 before GTx versus 8.5+/-1.7 after GTx, P:=0.047). CONCLUSIONS: The results of EMM constitute objective evidence that phVEGF(165) GTx augments perfusion of ischemic myocardium. These findings, together with reduction in the size of the defects documented at rest by serial single-photon emission CT-sestamibi imaging, suggest that phVEGF(165) GTx may successfully rescue foci of hibernating myocardium.


Subject(s)
Endothelial Growth Factors/genetics , Genetic Therapy/methods , Lymphokines/genetics , Myocardial Ischemia/therapy , Neovascularization, Physiologic , Angiogenesis Inducing Agents/therapeutic use , Coronary Circulation/drug effects , Electrocardiography/methods , Endothelial Growth Factors/therapeutic use , Gene Transfer Techniques , Heart/diagnostic imaging , Heart/physiopathology , Humans , Lymphokines/therapeutic use , Male , Microinjections , Middle Aged , Myocardial Ischemia/diagnostic imaging , Myocardial Ischemia/physiopathology , Plasmids/therapeutic use , Radionuclide Imaging , Thoracotomy , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Ventricular Function, Left
5.
Hum Gene Ther ; 10(18): 2953-60, 1999 Dec 10.
Article in English | MEDLINE | ID: mdl-10609656

ABSTRACT

Both VEGF protein and VEGF DNA in combination with an adenoviral vector have been shown to enhance collateral formation in a porcine model of chronic myocardial ischemia. We sought to determine whether direct intramyocardial injection of naked DNA encoding for VEGF could similarly improve myocardial perfusion. Initially, 23 nonischemic pigs received either 200 microg of plasmid DNA encoding beta-galactosidase (pCMVbeta, n = 11) or 500 microg of phVEGF165 (n = 12) into four separate sites in the myocardium via a small anterolateral thoracotomy incision in the fourth intercostal space. Two additional groups of pigs received an intramyocardial injection of either phVEGF165 (n = 6) or pCMVbeta (n = 7) 3 to 4 weeks after implantation of an ameroid constrictor around the left circumflex coronary artery. The injections caused no change in heart rate or blood pressure, and no ventricular arrhythmias or histologic evidence of inflammation. VEGF protein was detected by Western blot in VEGF-treated animals, with the strongest bands closest to the injection site. Plasma VEGF concentration (ELISA) increased from 3+/-2 to 27+/-13 pg/ml (p = 0.035) by day 4 after treatment. No increase in VEGF protein was noted in pCMVbeta-treated animals whereas these did stain positive for beta-Gal. Resting myocardial blood flow (colored microspheres) was significantly reduced in the ischemic versus nonischemic territory in control animals (1.07+/-0.05 versus 1.32+/-0.05; p < 0.05) but not VEGF-treated pigs (1.32+/-0.24 versus 1.13+/-0.12; p = NS). Maximal vasodilatation with adenosine significantly increased flow to the ischemic region in VEGF-treated pigs (2.16+/-0.57 versus 1.32+/-0.24; p < 0.05) but not controls (1.31+/-0.05 versus 1.17+/-0.06;p = NS). Collateral filling of the occluded circumflex artery improved in five of six VEGF-treated pigs (mean change in Rentrop score, +1.5). We conclude that direct intramyocardial transfection phVEGF165 is safe and capable of producing sufficient VEGF protein to enhance collateral formation and myocardial perfusion. This approach may offer an alternative therapy for patients with intractable myocardial ischemia not amenable to PTCA or CABG.


Subject(s)
Collateral Circulation , Coronary Vessels/physiopathology , DNA/administration & dosage , Endothelial Growth Factors/genetics , Genetic Therapy , Lymphokines/genetics , Myocardial Ischemia/therapy , Myocardium/metabolism , Animals , Disease Models, Animal , Gene Expression , Myocardial Ischemia/physiopathology , Swine , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , beta-Galactosidase/genetics
6.
Ann Thorac Surg ; 68(3): 830-6; discussion 836-7, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10509970

ABSTRACT

BACKGROUND: Patients presenting with medically intractable angina who have undergone previous coronary bypass (CABG) and/or percutaneous revascularization procedures are frequently deemed "inoperable" based on angiographic findings of diffuse distal disease or a lack of available conduits. We initiated a phase I clinical trial to assess the safety and bioactivity of intramyocardial transfection of plasmid DNA encoding for the angiogenic mitogen vascular endothelial growth factor (ph-VEGF165) in such patients. METHODS: phVEGF165 (125 microg, n = 10; 250 microg, n = 10) was injected directly into the myocardium through a mini left anterior thoracotomy as sole therapy in 20 patients (15 male, 5 female, age 48 to 74 years) with class III or IV angina, reversible ischemia on stress sestamibi scans, and "inoperable" coronary artery disease. RESULTS: All patients tolerated surgery uneventfully and were extubated on the table. No perioperative myocardial infarction, hemodynamic instability, or change in ventricular function occurred. Mean hospital stay was 3.9 days. There was one late death (4 months). Plasma VEGF protein level increased from 30.6+/-4.1 pg/mL pretreatment to 73.7+/-10.1 pg/mL 14 days posttreatment (p = 0.0002) and returned to baseline by day 90. All 16 patients followed to day 90 reported a reduction in angina (nitroglycerin use/week = 60.2+/-4.9 preop vs 3.5+/-1.6 at 90 days; p<0.0001). Seventy percent (7 of 10) patients were completely angina free at 6 months. A reduction in ischemic defects on single photon emission computerized tomography sestamibi scans was observed in 13 of 17 patients at 60 days (7 of 8 in the 250-microg group). Stress perfusion score decreased from 19.4+/-3.7 at baseline to 15.9+/-3.4 at 60 days (p = 0.025). Angiographic evidence of improved collateral filling of at least one occluded vessel was observed in all patients evaluated at day 60. CONCLUSIONS: Direct myocardial gene transfer with phVEGF165 via a mini-thoracotomy can be performed safely and may result in significant symptomatic improvement in patients with "inoperable" coronary artery disease.


Subject(s)
Coronary Disease/therapy , Endothelial Growth Factors/genetics , Genetic Therapy , Lymphokines/genetics , Aged , Coronary Angiography , Coronary Circulation , Coronary Disease/diagnostic imaging , Endothelial Growth Factors/blood , Escherichia coli , Female , Genetic Vectors , Humans , Lymphokines/blood , Male , Middle Aged , Technetium Tc 99m Sestamibi , Tomography, Emission-Computed, Single-Photon , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
7.
Hum Gene Ther ; 10(14): 2307-14, 1999 Sep 20.
Article in English | MEDLINE | ID: mdl-10515450

ABSTRACT

Gene transfer for therapeutic angiogenesis represents a novel treatment for patients with chronic angina refractory to standard medical therapy and not amenable to conventional revascularization. We sought to assess the role of intraoperative multiplane transesophageal echocardiography (MPTEE) in guiding injection of naked DNA encoding vascular endothelial growth factor (VEGF) into the left ventricular (LV) myocardium of patients with refractory angina. After exposing the LV myocardium via a limited lateral thoracotomy, each of 17 patients in this series received 4 separate injections of VEGF DNA into different myocardial sites. Initial injections in the first patient produced intracavitary microbubbles, indicating injection of DNA into the LV chamber. Subsequently, each injection was preceded by a test injection of agitated saline. The absence of microbubbles while visualizing the LV cavity during the test injection verified that the ensuing injection of DNA would not be inadvertently squandered in the LV chamber itself. Intracavitary LV microbubbles were observed by MPTEE in 13 of 64 (20.3%) saline test injections and in 8 of 16 (50.0%) patients in which saline test injection was used, leading to adjustments in needle position. MPTEE imaging detected a previously unknown large, apical left ventricular thrombus in one patient, thereby preventing inadvertent injection of VEGF DNA through the myocardium into the thrombus. Imaging during and after injection verified no deleterious impact on LV function. We conclude that MPTEE is a useful tool for ensuring that myocardial gene therapy performed by direct needle injection results in gene transfer to the LV myocardium.


Subject(s)
Angina Pectoris/therapy , Endothelial Growth Factors/genetics , Genetic Therapy , Lymphokines/genetics , Myocardium/metabolism , Aged , Angina Pectoris/diagnostic imaging , Angina Pectoris/physiopathology , Cardiac Surgical Procedures , Echocardiography, Transesophageal , Endothelial Growth Factors/metabolism , Female , Gene Transfer Techniques , Humans , Intraoperative Period , Lymphokines/metabolism , Male , Middle Aged , Plasmids/administration & dosage , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Ventricular Function, Left
8.
Circulation ; 98(25): 2800-4, 1998.
Article in English | MEDLINE | ID: mdl-9860779

ABSTRACT

BACKGROUND: We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia. METHODS AND RESULTS: VEGF gene transfer (GTx) was performed in 5 patients (all male, ages 53 to 71) who had failed conventional therapy; these men had angina (determined by angiographically documented coronary artery disease). Naked plasmid DNA encoding VEGF (phVEGF165) was injected directly into the ischemic myocardium via a mini left anterior thoracotomy. Injections caused no changes in heart rate (pre-GTx=75+/-15/min versus post-GTx=80+/-16/min, P=NS), systolic BP (114+/-7 versus 118+/-7 mm Hg, P=NS), or diastolic BP (57+/-2 versus 59+/-2 mm Hg, P=NS). Ventricular arrhythmias were limited to single unifocal premature beats at the moment of injection. Serial ECGs showed no evidence of new myocardial infarction in any patient. Intraoperative blood loss was 0 to 50 cm3, and total chest tube drainage was 110 to 395 cm3. Postoperative cardiac output fell transiently but increased within 24 hours (preanesthesia=4.8+/-0.4 versus postanesthesia=4.1+/-0.3 versus 24 hours postoperative=6. 3+/-0.8, P=0.02). Time to extubation after closure was 18.4+/-1.4 minutes; average postoperative hospital stay was 3.8 days. All patients had significant reduction in angina (nitroglycerin [NTG] use=53.9+/-10.0/wk pre-GTx versus 9.8+/-6.9/wk post-GTx, P<0.03). Postoperative left ventricular ejection fraction (LVEF) was either unchanged (n=3) or improved (n=2, mean increase in LVEF=5%). Objective evidence of reduced ischemia was documented using dobutamine single photon emission computed tomography (SPECT)-sestamibi imaging in all patients. Coronary angiography showed improved Rentrop score in 5 of 5 patients. CONCLUSIONS: This initial experience with naked gene transfer as sole therapy for myocardial ischemia suggests that direct myocardial injection of naked plasmid DNA, via a minimally invasive chest wall incision, is safe and may lead to reduced symptoms and improved myocardial perfusion in selected patients with chronic myocardial ischemia.


Subject(s)
Endothelial Growth Factors/genetics , Genetic Therapy/methods , Lymphokines/genetics , Myocardial Ischemia/therapy , Aged , Coronary Angiography , Humans , Injections, Intralesional , Male , Middle Aged , Minimally Invasive Surgical Procedures , Myocardial Ischemia/diagnostic imaging , Neovascularization, Physiologic , Plasmids/genetics , Thoracotomy/methods , Tomography, Emission-Computed, Single-Photon , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
9.
Arterioscler Thromb Vasc Biol ; 17(11): 2793-800, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9409257

ABSTRACT

In vitro studies suggest that vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) may stimulate release of nitric oxide (NO) from endothelial cells. To investigate the hemodynamic consequences of recombinant VEGF/VPF administered in vivo, recombinant human VEGF/VPF was administered as a bolus dose of 500 micrograms to anesthetized (n = 6) or conscious (n = 5) New Zealand White rabbits, as well as anesthetized rabbits with diet-induced hypercholesterolemia (HC; n = 7). Anesthetized Yorkshire farm pigs (no specific dietary pretreatment) were studied before and after receiving 500 micrograms intravenous (IV; n = 5) or intracoronary (IC; n = 5) VEGF/VPF. In anesthetized, normal rabbits, mean arterial pressure (MAP) fell by 20.5 +/- 1.4% (P < .05 versus baseline) within 3 minutes after IV VEGF/VPF. Pretreatment with N omega-nitro-L-arginine caused a significant inhibition of VEGF/VPF-induced hypotension. In conscious, normal rabbits, VEGF/VPF produced a consistent though lesser reduction in MAP. The fall in MAP induced by VEGF/VPF in anesthetized, HC rabbits (21.5 +/- 2.5% from baseline) was no different from that observed in normal anesthetized rabbits. In pigs, both IV and IC administration of VEGF/VPF produced a prompt reduction in MAP. Heart rate increased, while cardiac output, stroke volume, left atrial pressure, and total peripheral resistance all declined to a similar, statistically significant degree in both IV and IC groups. Epicardial echocardiography disclosed neither global nor segmental wall motion abnormalities in response to VEGF/VPF. We conclude that (1) VEGF/VPF-stimulated release of NO, previously suggested in vitro, occurs in vivo; (2) this finding suggests that functional VEGF/VPF receptors are present on quiescent adult endothelium, consistent with a maintenance function for VEGF/VPF, which may include regulation of NO; and (3) the preserved response of HC rabbits suggests that endothelial cell receptors for VEGF/VPF are spared in the setting of hypercholesterolemia.


Subject(s)
Endothelial Growth Factors/toxicity , Endothelium, Vascular/metabolism , Hypotension/chemically induced , Lymphokines/toxicity , Nitric Oxide/physiology , Animals , Aorta/drug effects , Cholesterol, Dietary/toxicity , Diet, Atherogenic , Echocardiography , Endothelial Growth Factors/pharmacology , Enzyme Inhibitors/pharmacology , Hemodynamics/drug effects , Humans , Hypercholesterolemia/etiology , Hypercholesterolemia/physiopathology , Hypotension/physiopathology , Lymphokines/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Nitroarginine/pharmacology , Rabbits , Receptor Protein-Tyrosine Kinases/drug effects , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/drug effects , Receptors, Growth Factor/physiology , Receptors, Vascular Endothelial Growth Factor , Recombinant Proteins/pharmacology , Recombinant Proteins/toxicity , Secretory Rate/drug effects , Swine , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Vasodilation/drug effects , omega-N-Methylarginine/pharmacology
10.
Am J Cardiol ; 74(8): 810-3, 1994 Oct 15.
Article in English | MEDLINE | ID: mdl-7942556

ABSTRACT

The reliability of automated acoustic quantification (AQ) in yielding real-time left ventricular (LV) area, volume, and ejection fraction has been validated. The purpose of this study was to explore the potential of AQ in providing accurate immediate determination of cardiac output in critically ill patients. A total of 48 patients were studied. One group consisted of 37 critically ill patients with indwelling Swan-Ganz catheters. In these patients, cardiac output by AQ, manual tracing of end-diastolic and end-systolic frames of 2-dimensional images, and thermodilution were measured. AQ was also compared with Doppler calculation of flow through the left and right ventricles in 11 additional patients. Adequate data for calculation of cardiac output with AQ were obtained in 78% of critically ill patients. There was an excellent correlation between AQ and off-line manual analysis for LV volumes (r = 0.94 and 0.91 for end-diastole and end-systole), ejection fraction (r = 0.85), and cardiac output (r = 0.93). AQ also correlated well with Doppler analysis (r = 0.97) and thermodilution technique (r = 0.95) in the determination of cardiac output. However, AQ slightly underestimated thermodilution measurements, with rather wide limits of agreement (-0.3 +/- 1.1 liter/min). There was a similar underestimation of cardiac output with manual analysis when compared with thermodilution. Given the absence of significant differences between AQ and manual analysis, this observation suggests that the bias is related to the echocardiographic determination of stroke volume, and not to errors from the automated border detection. It is concluded that AQ, besides providing information on LV volumes and ejection fraction, also can yield rapid measurements of cardiac output in most patients who are acutely ill.


Subject(s)
Cardiac Output , Critical Illness , Echocardiography, Doppler/methods , Image Processing, Computer-Assisted , Acoustics , Adolescent , Adult , Aged , Aged, 80 and over , Child , Humans , Middle Aged
11.
J Am Soc Echocardiogr ; 7(2): 174-8, 1994.
Article in English | MEDLINE | ID: mdl-8185963

ABSTRACT

The diagnosis and precise delineation of a pseudoaneurysm of the left ventricle have important implications regarding surgical planning and operative repair. A 68-year-old man was admitted to the hospital with the incidental finding of a large pseudoaneurysm of the left ventricle 6 months after a St. Jude mitral valve replacement performed for partial papillary muscle rupture after an acute myocardial infarction. Panoramic transesophageal echocardiography provided a full depiction of the left ventricle and the adjoining pseudoaneurysm, enhancing the preoperative evaluation of the extent of the defect. A successful repair was undertaken with a pericardial patch.


Subject(s)
Aneurysm, False/diagnostic imaging , Echocardiography, Transesophageal/methods , Heart Aneurysm/diagnostic imaging , Postoperative Complications/diagnostic imaging , Aged , Aneurysm, False/etiology , Follow-Up Studies , Heart Aneurysm/etiology , Heart Valve Prosthesis , Humans , Male , Mitral Valve , Myocardial Infarction/surgery , Postoperative Complications/epidemiology , Time Factors
12.
J Am Soc Echocardiogr ; 6(6): 619-23, 1993.
Article in English | MEDLINE | ID: mdl-8311970

ABSTRACT

A 38-year-old woman came for treatment with massive hemoptysis. A hilar density was observed on a chest radiograph. Transthoracic echocardiography demonstrated an intravascular pulmonary arterial mass that was studied in further detail with multiplane and panoramic transesophageal echocardiography. Surgical resection proved the mass to be a sarcoma arising from the main pulmonary artery. This case report demonstrates the utility of multiplane and panoramic transesophageal echocardiography in the study of intravascular tumors of the thorax.


Subject(s)
Echocardiography, Transesophageal/methods , Pulmonary Artery/diagnostic imaging , Sarcoma/diagnostic imaging , Soft Tissue Neoplasms/diagnostic imaging , Adult , Female , Humans , Pulmonary Artery/surgery , Sarcoma/surgery , Soft Tissue Neoplasms/surgery , Vascular Diseases/diagnostic imaging , Vascular Diseases/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...